These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24768778)

  • 1. Testing devices or experimental systems? Cancer clinical trials take the genomic turn.
    Nelson NC; Keating P; Cambrosio A; Aguilar-Mahecha A; Basik M
    Soc Sci Med; 2014 Jun; 111():74-83. PubMed ID: 24768778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker-driven patient selection for early clinical trials.
    Dienstmann R; Rodon J; Tabernero J
    Curr Opin Oncol; 2013 May; 25(3):305-12. PubMed ID: 23493192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology.
    Carroll KJ
    Pharm Stat; 2007; 6(4):253-60. PubMed ID: 17351904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncology trials gear up for high-throughput sequencing.
    Mullard A
    Nat Rev Drug Discov; 2012 Apr; 11(5):339-40. PubMed ID: 22543457
    [No Abstract]   [Full Text] [Related]  

  • 8. Dose-toxicity models in oncology.
    Adamina M; Joerger M
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):201-11. PubMed ID: 21241201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of tumor size response metrics to predict survival in oncology clinical trials.
    Bruno R; Mercier F; Claret L
    Clin Pharmacol Ther; 2014 Apr; 95(4):386-93. PubMed ID: 24419563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
    Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
    Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
    Park JW; Kerbel RS; Kelloff GJ; Barrett JC; Chabner BA; Parkinson DR; Peck J; Ruddon RW; Sigman CC; Slamon DJ
    Clin Cancer Res; 2004 Jun; 10(11):3885-96. PubMed ID: 15173098
    [No Abstract]   [Full Text] [Related]  

  • 16. Designing transformative clinical trials in the cancer genome era.
    Sleijfer S; Bogaerts J; Siu LL
    J Clin Oncol; 2013 May; 31(15):1834-41. PubMed ID: 23589555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A two-stage Bayesian design for co-development of new drugs and companion diagnostics.
    Karuri SW; Simon R
    Stat Med; 2012 May; 31(10):901-14. PubMed ID: 22238151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic biomarkers in model-based drug development in oncology.
    Keizer RJ; Schellens JH; Beijnen JH; Huitema AD
    Curr Clin Pharmacol; 2011 Feb; 6(1):30-40. PubMed ID: 21235464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances and challenges in the use of biomarkers in clinical trials.
    Chabner B
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):42-3. PubMed ID: 18322440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.